The blood-brain barrier (BBB) is a paradox. On one hand, it protects the brain from what would otherwise be a constant systemic barrage of noxious substances. On the other hand, it prevents, in large measure, the delivery of therapeutic agents to patients with brain tumors. In an ongoing effort to